BETAAccess all features while we're in beta! Some features may become paid later.Got feedback? Reach us 👉

Loading BBIO charts…

Search ticker or company⌘K

BBIO

01Multicharts 02Comparables 03Price target

May we use analytics cookies to see how vpside is used, including anonymous session recordings? Accepting also loads the price chart, which sets its own cookies. Essential cookies are always on. Privacy

BBIO · BridgeBio Pharma, Inc. fundamentals · vpside

vpside

⌘K

BBIOMarket cap $14.7B/Last filing 10-Q, Q3 FY26 · 29 Oct 2026/BBIOMarket cap $14.7B/Last filing 10-Q, Q3 FY26 · 29 Oct 2026/BBIOMarket cap $14.7B/Last filing 10-Q, Q3 FY26 · 29 Oct 2026/BBIOMarket cap $14.7B/Last filing 10-Q, Q3 FY26 · 29 Oct 2026/

Filings synced 13:22 · Prices: prior close 30 Oct

BBIO

BridgeBio Pharma, Inc.

Nasdaq · Pharmaceutical preparations (SIC 2834) · FY ends 31 Dec

01Multicharts 02Comparables 03Price target

Add a metric37 metrics

Revenue, quarterly

$353M+192.6% year on year

$400M$200M$0

vpside.com

Q4 ’21Q1 ’23Q2 ’24Q2 ’25Q3 ’26

Company filings · 10-Q filed 29 Oct 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

94.3%−1.4 pp year on year

100%80%60%40%

vpside.com

Q1 ’23Q1 ’24Q4 ’24Q4 ’25Q3 ’26

Company filings · 10-Q filed 29 Oct 2026 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$1.53B+138.5% year on year

$2B$1B$0

vpside.com

Q4 ’21Q1 ’23Q2 ’24Q2 ’25Q3 ’26

Company filings · 10-Q filed 29 Oct 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$370M

$250M$0−$250M−$500M−$750M

vpside.com

Q4 ’21Q1 ’23Q2 ’24Q2 ’25Q3 ’26

Company filings · 10-Q filed 29 Oct 2026 · TTM = last four quartersvpside.com

Chart 05 is empty

Chart 06 is empty

Fundamentals: company filings · Q4 = full year − nine months · TTM = last four quarters